Results 101 to 110 of about 17,554 (214)

Candesartan, Metoprolol and Rosuvastatin Associated to Lower 30-Days Mortality in Adult COVID-19 Patients - A Register Study in Finland before COVID-19 Vaccines. [PDF]

J Prim Care Community Health
Hyvärinen A, Helminen M, Broas M, Syrjälä H.   +3 more
europepmc   +1 more source

Candesartan cilexetil as a repurposed therapeutic candidate for nasopharyngeal carcinoma: Integrated in vitro and in silico analyses. [PDF]

EXCLI J
Ngernsombat C, Suriya U, Udompaisarn S, Panomchoeng N, Janvilisri T.   +4 more
europepmc   +1 more source

Review on cardioprotective strategies in the setting of chemotherapy-induced cardiotoxicity. [PDF]

Cardiooncology
Dao V, Amin S, Kammaripalle T, Manning K.   +3 more
europepmc   +1 more source

Surfactant-Enriched Cross-Linked Scaffold as an Environmental and Manufacturing Feasible Approach to Boost Dissolution of Lipophilic Drugs. [PDF]

Pharmaceutics
Sherif AY, Alshora DH, Ibrahim MA.
europepmc   +1 more source

Total Abdominal Hysterectomy in a Young Woman With Refractory Abnormal Uterine Bleeding of Multifactorial Etiology: A Case Report of an Incidental Hemorrhagic Ovarian Cyst in a Single Ovary. [PDF]

Cureus
de La Cruz TL, Mateus KP, Tawil AJ, Portilla RF, Valladares C.   +4 more
europepmc   +1 more source

Neuroprotective effects of candesartan in 3-nitropropionic acid-induced Huntington's disease: modulation of angiotensin and CREB/BDNF/PGC1-α signaling. [PDF]

Inflammopharmacology
Elgindy AM, Atwa AM, El-Awady EE, El-Sayed NM, El-Orabi NF.   +4 more
europepmc   +1 more source

Spotlight on the Pharmacoeconomics of Candesartan Cilexetil in Chronic Heart Failure and Hypertension

The addition of candesartan cilexetil (Atacand(R), Amias(R), Blopress(R), Kenzen(R), Ratacand(R)) to standard therapy for chronic heart failure (CHF) provided important clinical benefits at little or no additional cost in France, Germany, and the UK ...
Greg L. Plosker, Susan J. Keam
core  

Unlocking the potential of targeting the angiotensin II type 1 receptor in cancer. [PDF]

Oncogene
Butcher DR, Parris CN, Crichton SJ, Dempsey FC, Al-Ali HN.   +4 more
europepmc   +1 more source

Rapid Normalization of Amniotic Fluid Index Following Discontinuation of Olmesartan: A Case Report. [PDF]

AJP Rep
Van Oosbree A, Larson T, Conley H, Bridges M, Argoti P, Mari G.   +5 more
europepmc   +1 more source

Industrial Sustainable Decrystallizing Formulation to Enhance Dissolution of Candesartan Cilexetil: Overcoming Limitations of Traditional Solid Dispersion Approaches. [PDF]

Pharmaceutics
Ibrahim MA, Sherif AY, Alshora DH.
europepmc   +1 more source